| Literature DB >> 31736863 |
Keita Matsuura1,2, Masayuki Maeda3, Masayuki Satoh4, Ken-Ichi Tabei4, Tomohiro Araki5, Maki Umino6, Hiroyuki Kajikawa2, Naoko Nakamura2, Hidekazu Tomimoto1.
Abstract
Purpose: Deep brain stimulation (DBS) is an established therapy for Parkinson's disease (PD). However, deteriorating cognitive function after DBS is a considerable problem for affected patients. This study was undertaken to assess whether pulvinar findings in susceptibility-weighted imaging (SWI) can suggest cognitive worsening.Entities:
Keywords: Parkinson's disease; cognitive function; deep brain stimulation; diffusion-weighted imaging; pulvinar nuclei; susceptibility-weighted imaging
Year: 2019 PMID: 31736863 PMCID: PMC6834769 DOI: 10.3389/fneur.2019.01158
Source DB: PubMed Journal: Front Neurol ISSN: 1664-2295 Impact factor: 4.003
Figure 1Pulvinar hypointensity MRI of a 61-year-old man in DWI (A), FLAIR (B), and SWI (C).
Patient profile.
| Age | 62.1 ± 8.6 | |
| Sex (M:F) | 5:16 | |
| Disease duration (years) | 11.3 ± 6.3 | |
| DBS target | STN17 GPi4 | |
| Hoehn-Yahr stage (on state) | 2.4 ± 0.8 | 2.1 ± 0.9 |
| Hoehn-Yahr stage (off state) | 3.7 ± 0.8 | 2.7 ± 0.8 |
| UPDRS Part I | 3.0 ± 2.6 | 0.95 ± 1.28 |
| UPDRS Part II | 9.5 ± 6.2 | 8.0 ± 5.9 |
| UPDRS Part III | 18.3 ± 12.3 | 11.4 ± 8.5 |
| UPDRS Part IV | 7.4 ± 2.9 | 3.3 ± 2.7 |
| LEDD (mg) | 694 ± 294 | 427 ± 219 |
| L-Dopa (mg) | 376 ± 161 | 208 ± 121 |
| DA (use rate; %) | 86% | 81% |
| Entacapone (use rate; %) | 71% | 52% |
| Selegiline (use rate; %) | 24% | 24% |
| Zonisamide (use rate; %) | 33% | 38% |
| MMSE | 26.24 ± 3.38 | 25.86 ± 5.14 |
| FAB | 13.76 ± 3.08 | 14.75 ± 2.40 |
| TMT-A (s) | 200 ± 149 | 153 ± 81 |
| CES-D | 16.4 ± 13.0 | 13.2 ± 13.3 |
p < 0.05,
p < 0.01. DBS, deep brain stimulation; STN, subthalamic nucleus; GPi, internal segment of globus pallidus; UPDRS, the Unified Parkinson's disease rating scale; LEDD, levodopa equivalent daily dose; DA, dopamine agonist; MMSE, Mini-Mental State Examination; FAB, Frontal Assessment Battery; TMT, Trail Making Test; CES-D, the Center for Epidemiologic Studies Depression Scale.
Relationship between cognitive function and pulvinar hypointensity in SWI.
| Hypointensity | 5 | 6 | 6 | 5 | 5 | 6 |
| Isointensity | 10 | 0 | 9 | 1 | 10 | 0 |
Comparison between the worsened and stationary or better MMSE score groups.
| MMSE score | 26.3 ± 2.4 | 26.2 ± 3.8 | 0.937 |
| Change in | −6.0 ± 3.9 | 1.9 ± 2.3 | 0.00110 |
| Age (years) | 67.0 ± 6.5 | 60.1 ± 8.8 | 0.100 |
| Disease duration (years) | 10.3 ± 6.3 | 11.7 ± 6.7 | 0.666 |
| LEDD (mg) | 631 ± 410 | 719 ± 258 | 0.559 |
| Hoehn-Yahr stage | 3.0 ± 0.6/3.7 ± 0.8 | 2.2 ± 0.8/3.7 ± 0.9 | 0.075/0.577 |
| Pulvinar hypointensity | 83% (5/6) | 40% (6/15) | 0.072 |
MMSE, Mini-Mental State Examination; LEDD, levodopa equivalent daily dose; SWI, susceptibility-weighted imaging.
Figure 2Change in TMT-A (A) and FAB (B) before DBS therapy and 1 year after DBS therapy. The white circle represents the average.
Figure 3No significant correlation was found between SN area and MMSE score change (A), and a moderate correlation was found between SN area and UPDRS score 1 year postoperatively (B).
Relationship between cognitive function and the SN area in NMI.
| ≥12 | 12 | 1 |
| <12 | 4 | 4 |
Figure 4VBM analysis showing the difference between groups with and without pulvinar hypointensity in SWI. Left pulvinar volumes of the group with pulvinar hypointensity in SWI were smaller than those of the group without pulvinar hypointensity in SWI.